ARCHIVES

FDA News: FDA Approved A Supplemental New Drug Application For Nexavar Tablets (Sorafenib) For The Treatment Of Patients With Locally Recurrent Or Metastatic, Progressive, Differentiated Thyroid Carcinoma Refractory To Radioactive Iodine Treatment.

This article is from The Cancer Letter archive.

Vol. 39 No. 45 | December 17, 2013

Download PDF Visit The Full Archive

Related Articles

William Nelson Named Cancer Center Director At Johns Hopkins.

November 7, 2008

NCI Division To Promote Funds To Promote Collaboration.

February 18, 2000

Changes In Cooperative Groups As Result Of Move To DCT Topic Of Chairmen’s Meeting Sept. 16

August 22, 1975

Retrospective Data Clean-up Can’t Help C225 Phase II Trial; Protocol Far Too “Fuzzy”

March 8, 2002

Sebelius: Congress Harming Nation’s Investment in Science

October 4, 2013

Bill Would Harm Pancreatic Cancer Research – Scientists Warn Of Unintended Consequences

August 10, 2012